ABMD Results

Share price down 22% and… beat beat beat beat raise…

7:13 am Abiomed beats by $0.04, beats on revs; raises FY16 revs in-line (ABMD) :
•Reports Q2 (Sep) earnings of $0.17 per share, $0.04 better than the Capital IQ Consensus of $0.13; revenues rose 47.3% year/year to $76.3 mln vs the $74.56 mln Capital IQ Consensus.
•Co issues in-line guidance for FY16, raises FY16 revs to $305-315 mln from $300-310 mln vs. $310.34 mln Capital IQ Consensus Estimate.



• Protected PCI Utilization Growth of 70% in the U.S.
DANVERS, Mass. — October 29, 2015 – Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today reported second quarter fiscal 2016 revenue of $76.4 million, an increase of 47% compared to revenue of $51.9 million for the same period of fiscal 2015. Second quarter fiscal 2016 GAAP net income was $7.7 million or $0.17 per diluted share, an increase of 103% and 89% respectively, compared to GAAP net income of $3.8 million or $0.09 per diluted share for the prior year period.
Financial and operating highlights during the second quarter of fiscal 2016 include:

• Fiscal second quarter worldwide Impella® heart pump revenue totaled $71.7 million, an increase of 53% compared to revenue of $46.9 million during the same period of the prior fiscal year. U.S. revenue grew 59% to $66.7 million from $42.0 million in the prior fiscal year with patient usage up 48%.

• The installed base for Impella 2.5 grew by an additional 27 hospitals, bringing the installed customer base to 1,000 sites. As part of Abiomed’s continued Impella CP® heart pump launch, 45 new hospitals purchased Impella CP, bringing the total number of Impella CP U.S. sites to 739.

• The Impella RP® heart pump installed base has a goal of 60 sites for the entire fiscal year. As of the end of the second quarter, the Company is ahead of schedule, with an additional 31 hospitals that made initial purchases of the Impella RP during the quarter, bringing the total number to 54 Impella RP U.S. sites.

• Gross margin for fiscal second quarter 2016 was 84.1% compared to 81.5% in the second quarter of fiscal 2015.

• Income from operations for the second quarter of fiscal 2016 was $12.8 million, or 16.8% of revenue, compared to $4.2 million, or 8.0% of revenue in the prior year period.

• The Company generated $19 million in cash, cash equivalents and marketable securities, totaling $175.5 million as of September 30, 2015, compared to $156.4 million at June 30, 2015. The Company continues to have no debt.

• At its annual Investor Day on August 11, Abiomed outlined its long-term growth strategy and five-year vision for revenues and demonstrated future products in development, which can be accessed via webcast here: http://edge.media-server.com/m/p/ckvn5o7f. The future products, which were also recently displayed at the TCT 2015 conference, included:

• The Impella ECP™ (Expandable Cardiac Power) heart pump on a complete 9 Fr Impella catheter and pump;

• The Next Generation Impella CP with an increased flow of 4.5 liters/minute and smart sensor technology;

• The Impella 5.5, which can be implanted via axillary (without a sternotomy), is designed with a 19 Fr pump on a 9 Fr catheter for months of flow of 5.5 liters per minute and patient ambulation;
• The longer term Impella BTR™ (Bridge to Recovery) heart pump, which can also be implanted via axillary (without a sternotomy), is designed to provide up to a year of 5.5 plus flow driven by a wearable driver.

• The Company also announced the submission of its U.S Food & Drug Administration (FDA) pre-market approval (PMA) supplements in August. The supplements are requesting approval for the Impella family of heart pumps (Impella 2.5, Impella CP and Impella 5.0/LD). The submissions are requesting approval for a set of indications related to the use of the Impella devices in patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery. A request for a longer duration of support was also included.

• A key clinical paper titled, “Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience,” was published in the American Heart Journal during the second quarter. The paper, authored by Mauricio Cohen et al., analyzed the results of high risk PCI (percutaneous coronary intervention) patients in the U.S. Impella (now cVAD™) Registry and determined that real-world clinical outcomes with the Impella 2.5 appeared to be favorable and consistent compared with the randomized PROTECT II trial.

• Seth Bilazarian, MD, was announced as the new Vice President of Interventional Cardiology Programs at Abiomed on October 8.

• At the Cardiovascular Research Foundation’s (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific sessions in October, there were over 25 Impella heart pump presentations, 3 Protected PCI symposia and 5 live Impella heart pump cases.

“We have had an exciting start to fiscal year 2016 with first half revenue growth of 49% and establishment of Protected PCI™ as a new indication. As evidenced by our patient growth and awareness at TCT, Protected PCI has been validated by physicians that treat higher risk patients requiring percutaneous hemodynamic support in the cath lab,” said Michael R. Minogue, Chairman, President and Chief Executive Officer, Abiomed. “We are confident that in the years ahead, Abiomed will deliver strong growth, support new indications and countries, and launch new best in class products. As always, Abiomed is committed to meaningfully impacting the lives of our patients and helping our physicians improve outcomes.”

The Company is increasing its fiscal year 2016 guidance for total revenue to be in the range of $305 million to $315 million, up from $300 million to $310 million, representing an increase in revenue of 32% to 37% from the prior year.

The Company is updating its fiscal year guidance for GAAP operating margin to be in the range of 15% to 17%, from the previous guidance range of 14% to 16%.


I can’t find any bad info either. Were they having a CC? Where there huge whisper numbers? Problems with the device?

It did plunge below the 50dma, which will scare off trades and intermediate term growth investors. Let’s see if it holds the 200dma.

Finviz shows PE at 35 and forward PE at 90. That theoretically takes into account the new price, but maybe not because Yahoo says PE is about 27.

I getting tired of all these “wonderful opportunities”.


I getting tired of all these “wonderful opportunities”.
Yeh these perfect high growth high value 1YPEG investing opportunities are turning into a perfect storm What’s left not to fall out of bed?

I getting tired of all these “wonderful opportunities”.
Yeh these perfect high growth high value 1YPEG investing opportunities are turning into a perfect storm What’s left not to fall out of bed?


Another punch in the face, I am quite battered.

Long abmd


Yeh these perfect high growth high value 1YPEG investing opportunities are turning into a perfect storm What’s left not to fall out of bed?
LOL - they fell out of the top of a triple decker bunk bed.

Is this a) a stop raid, b) a sell on the news overdone or c) something bad that I am missing. If a) this would be an ideal buying opportunity, if b) a good buying opportunity although might be a better one in a few days and if c) could someone enlighten me so that I can stay away but everything I know about the company says it is not c).

1 Like

Shares of Abiomed were last seen trading down 22.5% at $76.33 Thursday, with a consensus analyst price target of $106.67 and a 52-week trading range of $26.50 to $110.68.

One possible explanation for the drop-off could very well be profit taking. Abiomed shares have more than doubled in 2015 and nearly tripled over the past 52 weeks. Not to mention, with such a stellar year so far, these positive results may not be enough for investors

Now below the 200dma on huge volume. Leaving like lemmings. Do we have resolve? We should.

So far a pierce of the 200dma but the close will be more important. 200 dma about 73.29 on my charts. 1st pierce was good for a scalp bounce of .50-2.00 for me. Fingers crossed for a hold at the eod.


“”"Traders Attributing Abiomed Selloff Following Strong Earnings Report To Less Than Expected Future Growth Possibilities
12:46 pm ET October 29, 2015 (Benzinga) Hot Stories Print

BZ NOTE: Abiomed shares are down ~25%. Traders tell Benzinga they view Abiomed stock appreciation over past year as very strong, having risen from ~$40 in Feb 2014 to a high of $110.68 in mid-August, which may be causing profit taking as the company’s growth story is not expected to remain as strong as it has been.“”

From TDAmeritrade

Trying to understand how an apparently good result leads to more than 25% fall in price. Just bought some.


1 Like

Lest we not forget what a sell off can look like, check the BOFI chart again

The first day had HUGE volume and sliced through the 50 and 200dma. Then a very nice bounce and then more puking.

ABMD looks tempting to some at this point and may well bounce tomorrow, but we should go nice and slow when adding. Are you ready to add to BOFI now that time has passed? Maybe not, so go slow.



Another punch in the face, I am quite battered

A classic case of battered Investor syndrome. I am calling 911.




Now below the 200dma on huge volume. Leaving like lemmings. Do we have resolve? We should.

I thought below the 200dma was a technical sign to sell?


From Motley Fool’s Todd Campbell:

Despite delivering strong sales and earnings growth, investors appear more than willing to book profit following a dramatic run-up in Abiomed’s share price this year.

Perhaps, investor profit-taking was sparked by the fact that Impella year-over-year sales growth, while strong at 53%, was down slightly from fiscal Q1, during which Impella sales grew 60%.Or maybe, investors were hoping for better revenue guidance that reflects a higher overall yearly increase. At the low point of their current guidance, Abiomed projects sales will be up 32% this year versus last year, which would seem to suggest a deceleration in year-over-year growth in the coming two quarters.

Nevertheless, the drop-off in Abiomed’s shares may be presenting healthcare investors with a unique opportunity to think long-term and pick-up a fast-growing medical device company on sale. Although no one knows when the selling will stop, Abiomed’s fast-growth and future products could mean that top and bottom line sales continue to climb faster than the market.

Read the whole thing at http://www.fool.com/investing/general/2015/10/29/why-abiomed…

  • Matt

What’s left not to fall out of bed?

No kidding, ant! I feel pounded to a pulp. Results not as bad as how I feel, but still.


1 Like

A classic case of battered Investor syndrome. I am calling 911.

Mhy stock’s fallen and it can’t get up!

1 Like